Found this mentioned on another board. Even though it was from back in 2017- it was helpful to see this background/perspective on the open-label extensions at this point in the game. There are also some recent articles on 'insights in clinical trial design' on the Clinical Leader site that got my attention (as I continue to face challenges in the area of clinical trials).

'Informative read on the process and significance of study protocol amendment for adding an open-label arm extension.'
"Use Extension Studies To Enhance Phase 3 Data"

https://www.clinicalleader.com/doc/use-extens...-data-0001